Prophylaxis of Neuropathic Pain by mémantine (MEMANTINE)

University Hospital, Clermont-Ferrand

Status and phase

Completed

Phase 3

Conditions

Neuropathic Pain

Treatments

Drug: Placebo : lactose

Drug: Memantine EBIXA®

Study type

Interventional

Funder types

Other

Identifiers

NCT01536314

CHU-0115

Details and patient eligibility

About

The aim of this study is to evaluate if memantine administered during 4 weeks beginning 2 weeks before surgery induces a decrease of painful intensity 3 months after surgery, compared to placebo group.

Full description

Enrollment

43 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

18 years old
patient suffering breast cancer with mastectomy/tumorectomy with or within cleaning 2 weeks after inclusion with or within pre-emptive chemotherapy

Exclusion criteria

Against-indication at memantine administration : hypersensitivity at active substance or excipients, hypertension, antecedent cerebrovascular accident, severe cardiac insufficiency
Diabetic patient (Type I and II)
Patient with medical or surgical antecedents
Patient receiving treatment with amantadine, ketamine, dextrometorphan, L-Dopa, dopaminergic, anticholinergic agonists, barbiturate, neuroleptic, IMAO, antispastic agents, dantrolen or baclofen, phenitoin, cimetidine, ranitidine, procainamide, quinidine, quinine, nicotine, hydrochlorothiazide, warfarine
Patient with alcohol addiction
Woman in childbearing age not using effective contraceptive method, pregnant or lactating woman
Patient who participated in another clinical trial, located in exclusion period or received benefits > 4500 euros during 12 months before the beginning of trial